Creative Medical Releases Data From StemSpine Procedure For Chronic Lower Back Pain
Portfolio Pulse from Vandana Singh
Creative Medical Technology Holdings Inc (NASDAQ:CELZ) announced positive topline pilot study results for the StemSpine procedure using AlloStem to treat chronic lower back pain. The data showed significant efficacy, no serious adverse events, and a reduction in narcotic usage, pain score, and Oswestry Score in treated patients.
May 18, 2023 | 5:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Creative Medical's StemSpine procedure using AlloStem showed positive results in treating chronic lower back pain, with significant efficacy and no serious adverse events.
The positive pilot study results indicate that the StemSpine procedure using AlloStem is effective in treating chronic lower back pain. This could lead to increased demand for the procedure and potentially boost the company's revenues and stock price in the short term. However, CELZ shares are currently down 8.05% at $0.61.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100